Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Presbyterian Hospital
mi
from
Charlotte, NC
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Children's Hospital Medical Center of Akron
mi
from
Akron, OH
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
The Children's Medical Center of Dayton
mi
from
Dayton, OH
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
The Children's Medical Center of Dayton
mi
from
Dayton, OH
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Legacy Emanuel Hospital and Health Center
mi
from
Portland, OR
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Legacy Emanuel Hospital and Health Center
mi
from
Portland, OR
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Oregon Health and Science University
mi
from
Portland, OR
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Geisinger Medical Center
mi
from
Danville, PA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Penn State Hershey Children's Hospital
mi
from
Hershey, PA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Penn State Hershey Children's Hospital
mi
from
Hershey, PA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Saint Christopher's Hospital for Children
mi
from
Philadelphia, PA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Saint Christopher's Hospital for Children
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Medical University of South Carolina
mi
from
Charleston, SC
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Greenville Cancer Treatment Center
mi
from
Greenville, SC
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Greenville Cancer Treatment Center
mi
from
Greenville, SC
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
T C Thompson Children's Hospital
mi
from
Chattanooga, TN
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
T C Thompson Children's Hospital
mi
from
Chattanooga, TN
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Cook Children's Medical Center
mi
from
Fort Worth, TX
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Baylor College of Medicine
mi
from
Houston, TX
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Scott & White Memorial Hospital
mi
from
Temple, TX
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Scott & White Memorial Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
University of Vermont
mi
from
Burlington, VT
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
University of Vermont
mi
from
Burlington, VT
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
University of Virginia
mi
from
Charlottesville, VA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Virginia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Providence Sacred Heart Medical Center & Children's Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
West Virginia University Charleston
mi
from
Charleston, WV
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
West Virginia University Charleston
mi
from
Charleston, WV
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Saint Vincent Hospital
mi
from
Green Bay, WI
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Saint Vincent Hospital
mi
from
Green Bay, WI
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
University of Wisconsin Hospital and Clinics
mi
from
Madison, WI
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Midwest Children's Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated:  10/30/2015
Sydney Children's Hospital
mi
from
Randwick,
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients With Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Status: Enrolling
Updated: 10/30/2015
Sydney Children's Hospital
mi
from
Randwick,
Click here to add this to my saved trials
Study of PM060184 in Patients With Advanced Solid Tumors
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  10/30/2015
START (South Texas Accelerated Research Therapeutics)
mi
from
San Antonio, TX
Study of PM060184 in Patients With Advanced Solid Tumors
Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 10/30/2015
START (South Texas Accelerated Research Therapeutics)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant (BMT) With High-dose Post Transplantation Cyclophosphamide.
Status: Enrolling
Updated:  10/30/2015
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide
Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant (BMT) With High-dose Post Transplantation Cyclophosphamide.
Status: Enrolling
Updated: 10/30/2015
Sidney Kimmel Comprehensive Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  10/30/2015
Columbia University Medical Center
mi
from
New York, NY
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 10/30/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  10/30/2015
University of Virginia
mi
from
Charlottesville, VA
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 10/30/2015
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated:  10/30/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Neoadjuvant Therapy for Ovarian Cancer
Feasibility of Carboplatin, Paclitaxel and Bevacizumab Neoadjuvant Therapy for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer
Status: Enrolling
Updated: 10/30/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Breast Cancer Risk Biomarkers in Postmenopausal Women
Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Breast Cancer Risk Biomarkers in Postmenopausal Women
Modulation of Breast Cancer Risk Biomarkers in Postmenopausal Women by High Dose Omega-3 Fatty Acids
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
Status: Enrolling
Updated:  10/30/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia
Status: Enrolling
Updated: 10/30/2015
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Accelerating Gastrointestinal Recovery
Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated:  10/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Accelerating Gastrointestinal Recovery
Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial
Status: Enrolling
Updated: 10/30/2015
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure
Status: Enrolling
Updated:  10/30/2015
University of Arkansas for Medical Sciences
mi
from
Little Rick, AR
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT) and Chemotherapy in Recurrent and Inoperable Squamous Cell Carcinoma (SCC) of the Head and Neck After Radiotherapy Failure
Status: Enrolling
Updated: 10/30/2015
University of Arkansas for Medical Sciences
mi
from
Little Rick, AR
Click here to add this to my saved trials
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated:  10/30/2015
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
LY353381 in Preventing Breast Cancer in Women With Hyperplasia
A Phase II Clinical Trial of a Selective Estrogen Receptor Modulator (LY353381*HCl) in High Risk Women With Fine Needle Aspiration Cytologic Evidence of Hyperplasia
Status: Enrolling
Updated: 10/30/2015
U.S. Oncology Research, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated:  10/30/2015
Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital
mi
from
Chicago, IL
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated: 10/30/2015
Lynn Sage Comprehensive Breast Center at Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated:  10/30/2015
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
mi
from
Kansas City, KA
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated: 10/30/2015
Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated:  10/30/2015
Oklahoma University Medical Center
mi
from
Oklahoma City, OK
Celecoxib in Preventing Breast Cancer in At-Risk Premenopausal Women
A Study to Identify Biomarker Modulation by a Cyclooxygenase-2 (COX-2) Inhibitor in Breast Tissue of Premenopausal Women at High Risk for Estrogen Receptor Negative (ERN) Breast Cancer
Status: Enrolling
Updated: 10/30/2015
Oklahoma University Medical Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Protocol for Women at Increased Risk of Developing Breast Cancer
Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Protocol for Women at Increased Risk of Developing Breast Cancer
Study of the Effect of Letrozole on Breast Biomarkers of High Risk Postmenopausal Women Receiving Hormone Replacement Therapy
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Protocol for Women at Increased Risk of Developing Breast Cancer
A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Protocol for Women at Increased Risk of Developing Breast Cancer
A Double-blinded Phase II Study of the Expression of Ki-67/MIB-1 in Women With Hyperplasia of the Breast Randomized to Receive Daily Celecoxib 400 mg BID or Placebo
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Status: Enrolling
Updated:  10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Modulation of Breast Cancer Risk Biomarkers by High Dose Vitamin D
Status: Enrolling
Updated: 10/30/2015
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Cord Blood Expansion on Mesenchymal Stem Cells
Cord Blood Expansion on Mesenchymal Stem Cells
Status: Enrolling
Updated:  11/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cord Blood Expansion on Mesenchymal Stem Cells
Cord Blood Expansion on Mesenchymal Stem Cells
Status: Enrolling
Updated: 11/2/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Health Literacy Intervention for Informed Consent of Cancer Patients Considering Clinical Trial Participation
A Mixed Methods Study to Reduce Disparities in Cancer Clinical Trials by Adapting a Health Literacy Intervention for Informed Consent and Comparing it to Usual Care in a Randomized Experiment
Status: Enrolling
Updated:  11/2/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Health Literacy Intervention for Informed Consent of Cancer Patients Considering Clinical Trial Participation
A Mixed Methods Study to Reduce Disparities in Cancer Clinical Trials by Adapting a Health Literacy Intervention for Informed Consent and Comparing it to Usual Care in a Randomized Experiment
Status: Enrolling
Updated: 11/2/2015
Siteman Cancer Center
mi
from
St. Louis, MO
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers
Status: Enrolling
Updated:  11/3/2015
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers
Status: Enrolling
Updated: 11/3/2015
Wayne State University/Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers
Status: Enrolling
Updated:  11/3/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
Phase I Study of IMC-A12 (NSC# 742460) in Combination With Temsirolimus CCI-779 (NSC# 683864) in Patients With Advanced Cancers
Status: Enrolling
Updated: 11/3/2015
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract
Status: Enrolling
Updated:  11/3/2015
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Phase II Trial of Neoadjuvant Dose Dense MVAC in Muscle Invasive Bladder Cancer and High Risk Urothelial Carcinoma of the Upper Urinary Tract
Status: Enrolling
Updated: 11/3/2015
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials